| Literature DB >> 34970575 |
Jia-Hui Gu1, Ting-Ting Gong1, Qi-Jun Wu2,3, Fang-Hua Liu2,3, Zhao-Yan Wen2,3, Chang Gao2,3, Yi-Fan Wei2,3, Zhuo Yang4.
Abstract
Background: As a result of a limited number of studies and inconsistent findings, there remains uncertainty in whether pre-diagnostic dietary supplements intake affects survival after ovarian cancer (OC) diagnosis.Entities:
Keywords: cohort; dietary supplements; mortality; ovarian cancer; prognosis; survival
Year: 2021 PMID: 34970575 PMCID: PMC8712326 DOI: 10.3389/fnut.2021.758178
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
General characteristics of patients with ovarian cancer (OC) according to dietary supplements intake (N = 703).
|
|
|
| |
|---|---|---|---|
|
|
| ||
|
| 150 | 553 | |
|
| 54.00 (47.00–61.00) | 53.00 (48.00–60.00) | 0.66 |
|
| 33.95 (19.77–47.87) | 30.60 (20.10–46.63) | 0.46 |
|
| 22.85 (20.40–24.70) | 23.30 (21.00–25.10) | 0.07 |
|
| 13.85 (7.30–22.90) | 14.10 (6.30–22.00) | 0.83 |
| Total energy (kcal/d) | 1584.58 ± 572.89 | 1420.81 ± 542.30 | <0.05 |
| Meat (g/day) | 40.69 ± 31.52 | 35.21 ± 28.81 | <0.05 |
| Dairy products (g/day) | 102.28 ± 126.41 | 79.05 ± 109.00 | <0.05 |
| Eggs (g/day) | 42.60 ± 28.10 | 36.44 ± 26.74 | <0.05 |
| Fish and seafood (g/day) | 32.13 ± 28.01 | 27.54± 30.85 | 0.10 |
| Beans and bean products (g/day) | 101.15 ± 81.45 | 80.96 ± 77.13 | <0.05 |
| Vegetables (g/day) | 225.66 ± 119.92 | 211.12 ± 122.12 | 0.19 |
| Fruits (g/day) | 209.63 ± 152.07 | 190.57 ± 159.22 | 0.19 |
|
| 0.08 | ||
| No | 106 (70.67) | 429 (77.58) | |
| Yes | 44 (29.33) | 124 (22.42) | |
|
| <0.05 | ||
| No | 142 (94.67) | 493 (89.15) | |
| Yes | 8 (5.33) | 60 (10.85) | |
|
| 0.96 | ||
| No | 118 (78.67) | 436 (78.84) | |
| Yes | 32 (21.33) | 117 (21.16) | |
|
| 0.30 | ||
| No | 107 (71.33) | 370 (66.91) | |
| Yes | 43 (28.67) | 183 (33.09) | |
|
| 0.62 | ||
| No | 44 (29.33) | 151 (27.31) | |
| Yes | 106 (70.67) | 402 (72.69) | |
|
| 0.57 | ||
| ≤ 1 | 105 (70.00) | 400 (72.33) | |
| ≥ 2 | 45 (30.00) | 153 (27.67) | |
|
| 0.86 | ||
| Junior secondary or below | 81 (54.00) | 294 (53.16) | |
| Senior high school/technical secondary school | 29 (19.33) | 118 (21.34) | |
| Junior college/university or above | 40 (26.67) | 141 (25.50) | |
|
| 0.18 | ||
| <5000 | 80 (53.33) | 341 (61.66) | |
| 5000 to <10000 | 49 (32.67) | 145 (26.22) | |
| ≥10000 | 21 (14.00) | 67 (12.12) | |
IQR, interquartile range; MET, metabolic equivalent task; SD, standard deviation.
Selected clinical characteristics and associations with all-cause mortality among women diagnosed with ovarian cancer (N = 703).
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
| ≤ 50 | 45/258 (17.44) | 1.00 (ref) | 1.00 (ref) | ||
| >50 | 85/445 (19.10) | 1.18 (0.82–1.70) | 0.37 | 1.24 (0.85–1.79) | 0.26 |
|
| |||||
| Serous | 92/479 (19.21) | 1.00 (ref) | 1.00 (ref) | ||
| Non-serous | 38/224 (16. 96) | 0.87 (0.59–1.27) | 0.47 | 1.71 (1.11–2.66) | <0.05 |
|
| |||||
| Well differentiated | 5/56 (8.93) | 1.00 (ref) | 1.00 (ref) | ||
| Moderately differentiated | 7/48 (14.58) | 1.44 (0.46–4.57) | 0.53 | 1.12 (0.35–3.57) | 0.85 |
| Poorly differentiated | 118/599 (19.70) | 2.32 (0.95–5.67) | 0.07 00 | 1.76 (0.70–4.43) | 0.23 |
|
| |||||
| I–II | 41/342 (11.99) | 1.00 (ref) | 1.00 (ref) | ||
| III–IV | 89/338 (26.33) | 2.75 (1.89–4.00) | <0.05 | 2.54 (1.65–3.91) | <0.05 |
|
| |||||
| No | 82/553 (14.83) | 1.00 (ref) | 1.00 (ref) | ||
| <1 cm | 31/106 (29.25) | 2.22 (1.47–3.36) | <0.05 | 1.73 (1.11–2.68) | <0.05 |
| ≥1 cm | 17/44 (38.64) | 3.18 (1.89–5.37) | <0.05 | 2.41 (1.39–4.16) | <0.05 |
|
| |||||
| No | 74/393 (18.83) | 1.00 (ref) | 1.00 (ref) | ||
| Yes | 56/310 (18.06) | 0.82 (0.58–1.16) | 0.27 | 0.97 (0.68–1.38) | 0.86 |
Mutually adjusted for all other variables listed in the table.
CI, confidence interval; HR, hazard ratio; ref, reference.
Hazard ratio (95% CI) for overall survival among patients with OC according to different dietary supplements intake.
|
|
|
|
|
|---|---|---|---|
|
| |||
| No. of deaths/total (%) | 106/553 (19.17) | 24/150 (16.00) | |
| Model 1 | 1.00 (ref) | 0.82 (0.53–1.28) | 0.37 |
| Model 2 | 1.00 (ref) | 0.75 (0.47–1.18) | 0.22 |
|
| |||
| No. of deaths/total (%) | 129/692 (18.64) | 1/11 (9.09) | |
| Model 1 | 1.00 (ref) | 0.42 (0.06–2.98) | 0.38 |
| Model 2 | 1.00 (ref) | 0.48 (0.07–3.46) | 0.46 |
|
| |||
| No. of deaths/total (%) | 126/691 (18.23) | 4/12 (33.33) | |
| Model 1 | 1.00 (ref) | 2.19 (0.81–5.94) | 0.12 |
| Model 2 | 1.00 (ref) | 3.78 (1.33–10.96) | <0.05 |
|
| |||
| No. of deaths/total (%) | 124/662 (18.73) | 6/41 (14.63) | |
| Model 1 | 1.00 (ref) | 0.79 (0.35–1.79) | 0.57 |
| Model 2 | 1.00 (ref) | 0.64 (0.27–1.54) | 0.32 |
|
| |||
| No. of deaths/total (%) | 128/694 (18.44) | 2/9 (22.22) | |
| Model 1 | 1.00 (ref) | 1.27 (0.31–5.12) | 0.74 |
| Model 2 | 1.00 (ref) | 1.19 (0.28–5.03) | 0.82 |
|
| |||
| No. of deaths/total (%) | 129/694 (18.59) | 1/9 (11.11) | |
| Model 1 | 1.00 (ref) | 0.69 (0.10–4.91) | 0.71 |
| Model 2 | 1.00 (ref) | 0.47 (0.06–3.87) | 0.48 |
|
| |||
| No. of deaths/total (%) | 127/672 (18.90) | 3/31 (9.68) | |
| Model 1 | 1.00 (ref) | 0.47 (0.15–1.48) | 0.20 |
| Model 2 | 1.00 (ref) | 0.49 (0.14–1.67) | 0.26 |
|
| |||
| No. of deaths/total (%) | 117/637 (18.37) | 13/66 (19.70) | |
| Model 1 | 1.00 (ref) | 1.11 (0.63–1.97) | 0.72 |
| Model 2 | 1.00 (ref) | 0.96 (0.53–1.72) | 0.88 |
|
| |||
| No. of deaths/total (%) | 130/698 (18.62) | 0/5 (0.00) | |
| Model 1 | 1.00 (ref) | – | |
| Model 2 | 1.00 (ref) | – | |
|
| |||
| No. of deaths/total (%) | 130/700 (18.57) | 0/3 (0.00) | |
| Model 1 | 1.00 (ref) | – | |
| Model 2 | 1.00 (ref) | – | |
|
| |||
| No. of deaths/total (%) | 129/685 (18.83) | 1/18 (5.56) | |
| Model 1 | 1.00 (ref) | 0.26 (0.04–1.83) | 0.17 |
| Model 2 | 1.00 (ref) | 0.31 (0.04–2.37) | 0.26 |
|
| |||
| No. of deaths/total (%) | 130/702 (18.52) | 0/1 (0.00) | |
| Model 1 | 1.00 (ref) | – | |
| Model 2 | 1.00 (ref) | – |
CI, confidence interval; HR, hazard ratio; ref, reference.
Model 1 adjusted for age at diagnosis.
Model 2 same as Model 1 and further adjusted for body mass index, diet change, dietary pattern, total energy intake, education, FIGO stage, histological type, histopathologic grade, menopausal status, parity, oral contraceptive use, physical activity, residual lesions, and smoke status.
Figure 1Kaplan-Meier survival curves for dietary supplements intake.